Amyris (NASDAQ:AMRS) Now Covered by StockNews.com

Posted by on Mar 19th, 2023

Equities researchers at StockNews.com started coverage on shares of Amyris (NASDAQ:AMRS – Get Rating) in a report issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other research analysts have also issued reports on the company. Piper Sandler dropped their price objective on Amyris from $2.00 to $1.50 in a research note on Thursday. HC Wainwright lowered their target price on Amyris from $22.00 to $5.00 in a research note on Thursday. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.63.

Amyris Price Performance

Amyris stock opened at $1.27 on Friday. The stock has a fifty day moving average price of $1.45 and a two-hundred day moving average price of $2.10. Amyris has a 52-week low of $0.99 and a 52-week high of $5.15. The firm has a market capitalization of $419.30 million, a P/E ratio of -0.72 and a beta of 1.10.

Hedge Funds Weigh In On Amyris

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Williams Jones Wealth Management LLC. bought a new position in Amyris during the first quarter worth about $45,000. FCA Corp TX bought a new position in shares of Amyris during the 1st quarter valued at about $48,000. Metropolitan Life Insurance Co NY lifted its holdings in shares of Amyris by 109.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 11,936 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 6,238 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in shares of Amyris during the 3rd quarter valued at about $36,000. Finally, Atom Investors LP bought a new position in shares of Amyris during the 3rd quarter valued at about $37,000. Institutional investors own 43.08% of the company’s stock.

Amyris Company Profile

(Get Rating)

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Featured Articles

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.